心脉医疗(688016) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥205,447,495.78, representing a year-on-year increase of 38.92%[7] - The net profit attributable to shareholders for Q3 2022 was ¥85,847,001.01, reflecting a year-on-year growth of 31.51%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥70,922,070.24, with a year-on-year increase of 32.96%[7] - Total operating revenue for the first three quarters of 2022 reached ¥664,247,489.74, a 30.2% increase from ¥510,158,422.03 in the same period of 2021[38] - Net profit for the third quarter of 2022 was ¥297,871,534.21, compared to ¥248,832,017.44 in the same quarter of 2021, representing a 19.7% increase[40] - Basic earnings per share for the third quarter of 2022 were ¥4.18, up from ¥3.47 in the same quarter of 2021, indicating a 20.4% increase[43] Research and Development - The total R&D investment for Q3 2022 was ¥42,246,946.26, which is an increase of 41.82% compared to the same period last year[11] - R&D investment accounted for 20.56% of operating revenue, an increase of 0.42 percentage points year-on-year[11] - Research and development expenses for the first three quarters of 2022 totaled ¥88,176,367.06, compared to ¥67,040,191.51 in the same period of 2021, marking a 31.5% increase[38] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,893,217,628.66, an increase of 7.96% compared to the end of the previous year[11] - The equity attributable to shareholders at the end of the reporting period was ¥1,661,667,699.27, reflecting an increase of 11.20% year-on-year[11] - The company's cash and cash equivalents decreased to RMB 1,040,567,606.76 from RMB 1,243,238,037.98 in the previous year, reflecting a decline of approximately 16.3%[29] - Accounts receivable increased to RMB 84,001,150.65, up from RMB 73,201,434.59, representing a growth of about 15%[29] - Inventory rose to RMB 133,392,734.72, compared to RMB 106,917,364.12, indicating an increase of approximately 24.7%[29] - The company's non-current assets totaled RMB 580,704,565.10, significantly up from RMB 294,949,685.80, marking an increase of around 96.8%[32] - Current liabilities decreased to RMB 143,522,131.37 from RMB 162,053,557.95, a reduction of about 11.4%[32] - Total liabilities decreased to ¥206,008,911.10 from ¥231,472,775.49, a reduction of approximately 11%[38] Cash Flow - The company reported a net cash flow from operating activities of ¥263,544,986.98 for the year-to-date, which is an increase of 17.84% compared to the same period last year[11] - The cash inflow from operating activities for the first three quarters of 2022 was RMB 765,900,437.99, an increase of 30.3% compared to RMB 587,186,784.48 in the same period of 2021[47] - The net cash flow from operating activities for the first three quarters of 2022 was RMB 263,544,986.98, up from RMB 223,648,012.35 in 2021, reflecting a growth of 17.8%[47] - The cash inflow from investment activities in the first three quarters of 2022 was RMB 2,033,836,685.94, significantly higher than RMB 716,982,478.55 in the same period of 2021, marking an increase of 184.5%[48] - The net cash flow from investment activities for the first three quarters of 2022 was negative RMB 323,228,387.03, an improvement from negative RMB 575,054,145.57 in 2021[48] - The cash outflow for purchasing fixed assets and other long-term assets in the first three quarters of 2022 was RMB 159,834,693.14, compared to RMB 42,036,624.12 in 2021, indicating a substantial increase[48] - The cash outflow from financing activities in the first three quarters of 2022 was RMB 159,755,427.87, compared to RMB 72,089,568.88 in 2021, showing an increase of 121.5%[48] Strategic Initiatives - The company held a board meeting on July 25, 2022, to approve plans for issuing A-shares to specific investors, indicating a strategic move for capital raising[26] - The company plans to implement a shareholder return plan for the next three years (2022-2024), focusing on dividend distribution[26] - The company expects continued growth in sales and profitability driven by increased sales scale and non-recurring gains[16]